Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267930
Status:
COMPLETED
Last Update Posted:
2008-12-18
First Post:
2005-12-20
Brief Title:
Study of RSD1235-SR for the Prevention of Atrial FibrillationAtrial Flutter Recurrence
Sponsor:
Advanz Pharma
Organization:
Advanz Pharma
Study Overview
Official Title:
A Pilot Phase II Randomised Double-Blind Placebo-Controlled Multi-Centred Safety Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial FibrillationAtrial Flutter AFAFL Recurrence in Subjects Post-Conversion Form AF
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the safety tolerability and preliminary efficacy of vernakalant oral in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None